id stringlengths 36 36 | study stringlengths 10 40 | full_paper stringlengths 759 115k | outcome stringlengths 2 127 | randomisation_process_judgment stringclasses 3
values | randomisation_process_reasoning stringclasses 39
values | intended_interventions_judgment stringclasses 3
values | intended_interventions_reasoning stringclasses 57
values | missing_outcome_data_judgment stringclasses 3
values | missing_outcome_data_reasoning stringclasses 63
values | measurement_outcome_judgment stringclasses 4
values | measurement_outcome_reasoning stringclasses 60
values | selection_reported_result_judgment stringclasses 3
values | selection_reported_result_reasoning stringclasses 47
values | overall_risk stringclasses 3
values |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
a6f07aad-d8d3-4020-9b2f-574c49834601 | 10.1097/HJH.0b013e328334c126 | # Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the $677 \mathrm{C} \rightarrow \mathrm{T}$ polymorphism in MTHFR
Geraldine Horigana, Helene McNultya, Mary Warda, J.J. Straina, John Purvisb and John M. Scottc
Objective The purpose was to examine the effect of intervention with r... | Systolic blood pressure | Low risk of bias | No information about allocation concealment, but a statement that the study is randomised. We judged that the allocation sequence was probably concealed until participants were enrolled and assigned to the intervention. There was no information on baseline differences between the groups – a table of baseline characteri... | High risk of bias | Excluded 18 participants from the analyses after randomisation (including 2 outliers). | High risk of bias | BP data was presented for 179 of 197 participants (91%). Data excluded from 2 participants because their values for BP were outliers. Data also excluded from 16 other paritipcnats for a variety of resaons, the most common being 'not contactable or withdrew voluntaryily' (n=7). | Low risk of bias | BP measured in standard way (two separate measurements taken 15 min apart with patient at rest). Outcome assessor was blinded to intervention status. | Some concerns | No information about whether data were analysed in accordance with a pre-specified analysis plan that was finalised before unblinded outcome data were available. | High risk of bias |
b4f4d777-2b63-4252-a76f-40fbf01244da | 10.1212/wnl.50.2.466 | # Effectiveness of high-dose riboflavin in migraine prophylaxis
A randomized controlled trial
J. Schoenen, MD, PhD; J. Jacquy, MD; and M. Lenaerts, MD
Article abstract—A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis. We found in a previous open study that high-dose riboflavin wa... | Adverse events | Low risk of bias | The allocation sequence was concealed and known only to the pharmacist who prepared the study material. | Low risk of bias | Participants and investigators were blinded and there was no apparent deviations from the intended intervention. | Low risk of bias | 5 people were excluded from the analysis after randomisation out of 55 people randomised. | Low risk of bias | Investigators were blinded to intervention status. | Some concerns | No information about whether data were analysed in accordance with a pre-specified analysis plan that was finalised before unblinded outcome data were available. | Some concerns |
3ce32920-d4f7-4b67-84ef-50330dedd6e8 | 10.1093/eurheartj/ehz745.0428 | P3566
# Ambulatory blood pressure response to riboflavin supplementation in adults with the C677T polymorphism in the folate metabolising enzyme methylenetetrahydrofolate reductase (MTHFR)
M. Ward<sup>1</sup>, C.F. Hughes<sup>1</sup>, A. Mc Mahon<sup>1</sup>, M. Rooney<sup>1</sup>, J.J. Strain<sup>1</sup>, R. Plumb<s... | Systolic blood pressure | High risk of bias | No information about allocation concealment, but a statement that the study is randomised. Large imbalances in sex and moderate differences in BP that were very unlikely to be due to chance, and most likely because only the results from participants with SBP of 125 mmHg or more at baseline were presented. | High risk of bias | Analyses excluded eligible participants who had baseline SBP under 125 mmHg. | High risk of bias | No outcome data was presented for participants who had baseline SBP under 125 mmHg. | Low risk of bias | Trial registry information describes the trial as double-blind (participants and investigators blinded). | High risk of bias | The results from only a subset of participants are presented, which suggests the numerical result may have been selected on the basis of multiple analyses of the data. | High risk of bias |
c1f1f0d8-6e51-4e6d-a36f-a470162f4522 | 10.1161/HYPERTENSIONAHA.111.01047 | # Stratified Treatment of Hypertension
# Blood Pressure in Treated Hypertensive Individuals With the MTHFR 677TT Genotype Is Responsive to Intervention With Riboflavin Findings of a Targeted Randomized Trial
Carol P. Wilson, Helene McNulty, Mary Ward, J.J. Strain, Tom G. Trouton, Birgit A. Hoeft, Peter Weber, Franz F... | Systolic blood pressure | Low risk of bias | No information about allocation concealment, but a statement that the study is randomised. We judged that the allocation sequence was probably concealed until participants were enrolled and assigned to the intervention. There are some differences in baseline characteristics between group, although none are statisticall... | High risk of bias | 4 outliers were removed for BP. | High risk of bias | There were 3 drop outs. In addition data from 4 participants was excluded because their values for BP were outliers. | Low risk of bias | Outcome assessor was blinded to intervention status. | Some concerns | No information about whether data were analysed in accordance with a pre-specified analysis plan that was finalised before unblinded outcome data were available. | High risk of bias |
2ac14668-0317-41e4-b567-daebbd19a146 | 10.1097/HJH.0b013e328334c126 | # Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the $677 \mathrm{C} \rightarrow \mathrm{T}$ polymorphism in MTHFR
Geraldine Horigana, Helene McNultya, Mary Warda, J.J. Straina, John Purvisb and John M. Scottc
Objective The purpose was to examine the effect of intervention with r... | Diastolic blood pressure | Low risk of bias | No information about allocation concealment, but a statement that the study is randomised. We judged that the allocation sequence was probably concealed until participants were enrolled and assigned to the intervention. There was no information on baseline differences between the groups – a table of baseline characteri... | High risk of bias | Excluded 18 participants from the analyses after randomisation (including 2 outliers). | High risk of bias | BP data was presented for 179 of 197 participants (91%). Data excluded from 2 participants because their values were outliers. Data excluded from 16 other participants for a variety of reasons, the most common being 'not contactable or withdrew voluntarily' (n=7). | Low risk of bias | BP measured in standard way (two separate measurements taken 15 min apart with patient at rest). Outcome assessor was blinded to intervention status. | Some concerns | No information about whether data were analysed in accordance with a pre-specified analysis plan that was finalised before unblinded outcome data were available. | High risk of bias |
6b06eef4-8524-4b97-b1b6-416d9ef15b9b | 10.1161/HYPERTENSIONAHA.111.01047 | # Stratified Treatment of Hypertension
# Blood Pressure in Treated Hypertensive Individuals With the MTHFR 677TT Genotype Is Responsive to Intervention With Riboflavin Findings of a Targeted Randomized Trial
Carol P. Wilson, Helene McNulty, Mary Ward, J.J. Strain, Tom G. Trouton, Birgit A. Hoeft, Peter Weber, Franz F... | Diastolic blood pressure | Low risk of bias | No information about allocation concealment, but a statement that the study is randomised. We judged that the allocation sequence was probably concealed until participants were enrolled and assigned to the intervention. There are some differences in baseline characteristics between group, although none are statisticall... | High risk of bias | 4 outliers were removed for DBP. | High risk of bias | There were 3 drop outs and 4 outliers excluded out of 91 randomised. | Low risk of bias | Outcome assessor was blinded to intervention status. | Some concerns | No information about whether data were analysed in accordance with a pre-specified analysis plan that was finalised before unblinded outcome data were available. | High risk of bias |
831f1327-9019-4db6-b625-26231f7c5533 | 10.1016/j.healun.2010.11.009 | "# Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hy(...TRUNCATED) | clinical worsening | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias |
36979232-c25d-43e2-ac00-1a5f7d99677c | 10.1016/j.healun.2010.11.009 | "# Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hy(...TRUNCATED) | clinical worsening | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias |
dc00bdfa-bfd9-4c1f-a981-72237fcf5730 | 10.1016/j.healun.2010.11.009 | "# Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hy(...TRUNCATED) | clinical worsening | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias |
d1cae5ac-c6d1-4dfe-bdc9-29c93bc7d775 | 10.1016/j.healun.2010.11.009 | "# Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hy(...TRUNCATED) | Death | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias | null | Low risk of bias |
LogiMed-RoB Dataset
LogiMed-RoB accompanies the paper “Can LLMs Follow Medical Expert Logic? A Benchmark for Hierarchical Logical Consistency in Risk-of-Bias Assessment.” It evaluates whether large language models follow the hierarchical expert logic used in clinical Risk-of-Bias (RoB) assessment, rather than merely matching final labels.
The release contains 860 randomized controlled trials (RCTs) and 14,820 structured queries across two complementary tracks. Gold-standard labels originate from expert assessments in Cochrane systematic reviews, peer-reviewed publications, ROBIN, and RoBBR. No AI-generated pseudo-labels are used.
Dataset configurations
| Configuration | Standard | RCTs | Items | Structured queries | Sources |
|---|---|---|---|---|---|
track_a |
Cochrane RoB 2.0 | 201 | 626 | 13,772 | Cochrane (467), Figshare (159) |
track_b |
Cochrane RoB 1.0 | 659 | 1,048 | 1,048 | ROBIN (713), RoBBR (335) |
Track A contains 22 rule-based signaling queries per assessment. Track B contains one evidential-faithfulness query per item.
Files
| File | Description |
|---|---|
RCT_ROB2_final_dataset.json |
Track A: RoB 2.0 outcome-level assessments with full RCT text, outcome descriptions, domain judgments, expert rationales, and overall risk labels. |
ssr_dataset_merged.json |
Track B: RoB 1.0 evaluation items with signaling questions, expert labels, evidence windows, answers, and rationales. |
Both files are UTF-8 JSON arrays and are exposed as a test split because LogiMed-RoB is an evaluation benchmark rather than a training corpus.
Loading the dataset
from datasets import load_dataset
track_a = load_dataset(
"BUPT-Reasoning-Lab/LogiMed-RoB",
"track_a",
split="test",
)
track_b = load_dataset(
"BUPT-Reasoning-Lab/LogiMed-RoB",
"track_b",
split="test",
)
Download the complete repository with the Hugging Face CLI:
hf download BUPT-Reasoning-Lab/LogiMed-RoB \
--repo-type dataset \
--local-dir ./LogiMed-RoB
Data format
Track A: RCT_ROB2_final_dataset.json
Each entry contains the following fields:
{
"id": "<uuid>",
"study": "<study identifier>",
"full_paper": "<Markdown text of the RCT paper>",
"outcome": "<target outcome>",
"randomisation_process_judgment": "<risk label>",
"randomisation_process_reasoning": "<expert rationale>",
"intended_interventions_judgment": "<risk label>",
"intended_interventions_reasoning": "<expert rationale>",
"missing_outcome_data_judgment": "<risk label>",
"missing_outcome_data_reasoning": "<expert rationale>",
"measurement_outcome_judgment": "<risk label>",
"measurement_outcome_reasoning": "<expert rationale>",
"selection_reported_result_judgment": "<risk label>",
"selection_reported_result_reasoning": "<expert rationale>",
"overall_risk": "<risk label>"
}
The RoB 2.0 domains are:
- Bias arising from the randomisation process.
- Bias due to deviations from intended interventions.
- Bias due to missing outcome data.
- Bias in measurement of the outcome.
- Bias in selection of the reported result.
Track B: ssr_dataset_merged.json
Each entry contains the following fields:
{
"id": "<uuid>",
"study": "<study identifier>",
"bias": "<bias domain>",
"question": "<signaling question>",
"label": "low | high | unclear",
"context_list": ["<evidence sentence>", "..."],
"answers": [
{
"answer": "yes | no | unclear",
"reason": "<expert rationale>"
}
]
}
Quality assurance
- Track A: all 626 items were manually extracted and calibrated against published expert conclusions; 467 are allocated to Cochrane and 159 to Figshare.
- Track B: approximately 20% of the release (210 items) was independently re-verified by medical annotators, with 93.5% agreement on evidence-window accuracy.
- No AI-generated pseudo-labels are included in either track.
Responsible use and source terms
LogiMed-RoB is intended for research on model evaluation, evidence-based medicine, and clinical reasoning. It must not be used as an autonomous clinical decision-making system.
The release incorporates material derived from Cochrane Library, Figshare, ROBIN, and RoBBR. Use and redistribution of individual records remain subject to the terms of their original sources; therefore the dataset card uses the Hugging Face other license designation. Consult the source projects and accompanying paper for provenance details.
Project resources
- Code and documentation: https://github.com/BUPT-Reasoning-Lab/LogiMed-RoB
- Dataset: https://huggingface.co/datasets/BUPT-Reasoning-Lab/LogiMed-RoB
Citation
@misc{huang2026logimedrob,
title = {Can LLMs Follow Medical Expert Logic? A Benchmark for Hierarchical Logical Consistency in Risk-of-Bias Assessment},
author = {Huang, Jiayu and Tang, Zichen and Ling, Qianhui and Kuang, Zemin and E, Haihong},
year = {2026},
url = {https://github.com/BUPT-Reasoning-Lab/LogiMed-RoB}
}
- Downloads last month
- 45